• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (3)
    • beta-Thalassemia
    • Cyclophosphamide versus placebo in scleroderma lung disease.
    • Evolutionarily conserved sequence motif analysis guides development of chemically defined hydrogels for therapeutic vascularization.
    • See All 3 Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Cyclophosphamide versus placebo in scleroderma lung disease.

Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.

View in: PubMed

subject areas
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoimmune Diseases
  • Bronchoalveolar Lavage Fluid
  • Cyclophosphamide
  • Double-Blind Method
  • Female
  • Humans
  • Immunosuppressive Agents
  • Leukopenia
  • Lung Diseases, Interstitial
  • Male
  • Middle Aged
  • Regression Analysis
  • Respiratory Function Tests
  • Scleroderma, Systemic
  • Treatment Outcome
  • Vital Capacity

authors with profiles
  • Richard M. Silver
  • Marcy B. Bolster